BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Titz B, Gadaleta RM, Lo Sasso G, Elamin A, Ekroos K, Ivanov NV, Peitsch MC, Hoeng J. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.Int J Mol Sci. 2018;19. [PMID: 30223557 DOI: 10.3390/ijms19092775] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Curry E, Philpott ME, Wojtusik J, Haffey WD, Wyder MA, Greis KD, Roth TL. Label-Free Quantification (LFQ) of Fecal Proteins for Potential Pregnancy Detection in Polar Bears. Life 2022;12:796. [DOI: 10.3390/life12060796] [Reference Citation Analysis]
2 Lice I, Sanches JM, Correia-silva RD, Corrêa MP, Icimoto MY, Silva AAR, Sánchez-vinces S, Porcari AM, Moreira V, Gil CD. Effects of Formyl Peptide Receptor Agonists Ac9-12 and WKYMV in In Vivo and In Vitro Acute Inflammatory Experimental Models. Cells 2022;11:228. [DOI: 10.3390/cells11020228] [Reference Citation Analysis]
3 Han X, Gross RW. The Foundations and Development of Lipidomics. J Lipid Res 2021;:100164. [PMID: 34953866 DOI: 10.1016/j.jlr.2021.100164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
4 Lee EG, Yoon YC, Yoon J, Lee SJ, Oh YK, Kwon SW. Systematic Review of Recent Lipidomics Approaches Toward Inflammatory Bowel Disease. Biomol Ther (Seoul) 2021;29:582-95. [PMID: 34565718 DOI: 10.4062/biomolther.2021.125] [Reference Citation Analysis]
5 Sun XL, Qiao LC, Gong J, Wen K, Xu ZZ, Yang BL. Proteomics identifies a novel role of fibrinogen-like protein 1 in Crohn’s disease. World J Gastroenterol 2021; 27(35): 5946-5957 [PMID: 34629811 DOI: 10.3748/wjg.v27.i35.5946] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. J Clin Med 2021;10:4219. [PMID: 34575330 DOI: 10.3390/jcm10184219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Park J, Jeong D, Chung YW, Han S, Kim DH, Yu J, Cheon JH, Ryu JH. Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet's disease from Crohn's disease. Sci Rep 2021;11:11019. [PMID: 34040049 DOI: 10.1038/s41598-021-90250-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Sidorina A, Catesini G, Levi Mortera S, Marzano V, Putignani L, Boenzi S, Taurisano R, Garibaldi M, Deodato F, Dionisi-Vici C. Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding. J Inherit Metab Dis 2021;44:705-17. [PMID: 33325062 DOI: 10.1002/jimd.12344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lo Sasso G, Khachatryan L, Kondylis A, Battey JND, Sierro N, Danilova NA, Grigoryeva TV, Markelova MI, Khusnutdinova DR, Laikov AV, Salafutdinov II, Romanova YD, Siniagina MN, Vasiliev IY, Boulygina EA, Solovyeva VV, Garanina EE, Kitaeva KV, Ivanov KY, Chulpanova DS, Kletenkov KS, Valeeva AR, Odintsova AK, Ardatskaya MD, Abdulkhakov RA, Ivanov NV, Peitsch MC, Hoeng J, Abdulkhakov SR. Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients. Inflamm Bowel Dis 2021;27:418-33. [PMID: 32766755 DOI: 10.1093/ibd/izaa188] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
10 Yan C, Guo H, Ding Q, Shao Y, Kang D, Yu T, Li C, Huang H, Du Y, Wang H, Hu K, Xie L, Wang G, Liang Y. Multiomics Profiling Reveals Protective Function of Schisandra Lignans against Acetaminophen-Induced Hepatotoxicity. Drug Metab Dispos 2020;48:1092-103. [PMID: 32719086 DOI: 10.1124/dmd.120.000083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kumar M, Garand M, Al Khodor S. Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine. J Transl Med 2019;17:419. [PMID: 31836022 DOI: 10.1186/s12967-019-02174-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
12 Zhang Y, Takagi N, Yuan B, Zhou Y, Si N, Wang H, Yang J, Wei X, Zhao H, Bian B. The protection of indolealkylamines from LPS-induced inflammation in zebrafish. J Ethnopharmacol 2019;243:112122. [PMID: 31356965 DOI: 10.1016/j.jep.2019.112122] [Cited by in Crossref: 9] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kalenyak K, Heilmann RM, van de Lest CHA, Brouwers JF, Burgener IA. Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment. PLoS One 2019;14:e0215435. [PMID: 30990833 DOI: 10.1371/journal.pone.0215435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
14 Li YH, Sun W, Zhou BJ, Rosenstein A, Zhao J, Wang J, Bian ZX. iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promising therapy for ulcerative colitis. Eur J Pharmacol 2019;850:167-79. [PMID: 30771347 DOI: 10.1016/j.ejphar.2019.02.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]